Glioma

CORRIGENDUM
Year
: 2022  |  Volume : 5  |  Issue : 3  |  Page : 110--111

Corrigendum: Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study


 

Correspondence Address:




How to cite this article:
. Corrigendum: Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study.Glioma 2022;5:110-111


How to cite this URL:
. Corrigendum: Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study. Glioma [serial online] 2022 [cited 2023 Jan 28 ];5:110-111
Available from: http://www.jglioma.com/text.asp?2022/5/3/110/358551


Full Text



In the article titled “Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study,” published on pages 29-38, Issue 1, Volume 5 of Glioma,[1] [Figure 1] has been incorrectly published. The correct [Figure 1] is given below.{Figure 1}

The authors apologize for any inconvenience this correction may cause for readers and editors of Glioma.

References

1Lin F, Guo C, Yang Q, Chen Y, Ke C, Sai K, et al. Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study. Glioma 2022;5:29-38.